Axovant Sciences Ltd AXON shares are trading lower by $17.65, or 72 percent, at $6.60 in Tuesday's session.
The catalyst for the sharp decline is the announcement that is Phase 3 Intepirdine MINDSET clinical trial did not meet its co-primary efficacy endpoints. The drug is being tested for use with patients with Alzheimer's disease.
After a much lower open, Axovant attempted to rally but found sellers at $7.40 and resumed its move lower. It went on to breach its opening print of $6.37, but only fell to $6.13 and is attempting to rebound.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
